[Cavinton forte treatment of cerebral vascular insufficiency in patients with coronary heart disease and arterial hypertension].
Using 48-h Holter monitoring of ECG and ambulatory blood pressure monitoring, 28 patients (13 men, 15 women, mean age 66.6 +/- 7.7 years) with cerebral vascular insufficiency of the I-II stage in combination with chronic coronary heart disease and essential arterial hypertension have been examined. Quantitative parameters of myocardial ischemia episodes and hypotension conditions were calculated and compared before the beginning (the first 24 h of monitoring) and during taking the daily dose of 30 mg of cavinton forte (the second 24 hours of monitoring). The distribution of ischemia and hypotension episodes in the periods of the maximal supposed effect of the drug was analyzed. Cavinton forte neither contributes to the manifestation and average frequency of myocardial ischemia episodes nor influences parameters and the character of short-term arterial hypotension episodes. The drug reduces quantity and duration of blood pressure nocturnal fall. It is concluded that initial cavinton forte treatment of cerebral vascular insufficiency in patients with chronic coronary heart disease in combination with arterial hypertension is safe when combined with hemodynamically active antihypertensive and antiischemic therapy.
Protasov
K V
KV
Dzizinskiĭ
A A
AA
Shprakh
V V
VV
Sinkevich
D A
DA
Kuklin
S G
SG
Filatova
L N
LN
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D002561:Cerebrovascular Disorders / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003327:Coronary Disease / Q000150:complications* / Q000503:physiopathology; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D016896:Treatment Outcome; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D018696:Neuroprotective Agents; D014748:Vinca Alkaloids; C013983:vinpocetine